September 15, 2020
Australia based Rhinomed Limited announced today they are developing a nasal swab.
Rhinomed notes this new high-yielding nasal swab that can collect samples from the nose to test for the presence of upper respiratory tract diseases, including influenza and coronavirus strains.
While the new swab will use standard electrostatically flocked nylon to capture sample material, Rhinomed has leveraged the learnings from its class-leading US FDA and Australian TGA-registered nasal devices Mute (anti-snoring), Pronto (anti-nasal-congestion and sleep improvement), and Turbine (improved breathing for sports) to create a new nasal swab that the company believes has compelling benefits over products currently on the market.
Rhinomed’s nasal swab is designed to be:
- Less invasive and more comfortable than standard nasopharyngeal swabs;
- Unique in that it collects a sample from both nostrils simultaneously;
- Able to collect samples from a far greater surface area of the nose than normal swabs;
- Able to be self-administered easily, anywhere, reducing the risk of infection of healthcare workers; and
- Able to be used by a wide number of people, every day
The new Rhinomed swab is designed to be able to collect a significantly larger sample, be worn for a predetermined time (it remains snugly in place), and collect a sample from both nostrils simultaneously, thus offering the potential for a more effective diagnostic sample. The swab has been designed to fit into existing vials and work with existing pathology workflows.
The Company is now rapidly scoping out manufacturing and is assessing additive manufacturing (3D printing) solutions, existing offshore manufacturing resources and scoping out the possibility of local manufacturing. The company will register the device in Australia, the USA, and in the European Union as a Class 1 medical device and has begun defining the protocol for a clinical trial to be carried out at a leading Melbourne hospital.
Rhinomed is advancing discussions with potential commercial partners in respect to the program. Further details on the clinical and commercial program will be announced in due course as they are finalized.
This announcement has been authorized for release by the Board.